Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Xu S, Heimberger AB  
Emerging Immune Therapeutics Targeting Glioblastoma-Mediated Immune Suppression: Dark Before the Dawn

European Association of NeuroOncology Magazine 2013; 3 (1): 15-22

PDF    Summary    Figures   

Fig. 1: Glioblastoma

Keywords: clinical trialglioblastomaimmunotherapy

As the most common and particularly devastating primary brain malignancy, glioblastoma exerts profound immunosuppression on the anti-tumour weapons of the immune system, which also poses a tremendous obstacle to immunotherapy. By targeting glioblastomamediated immune suppression, enthusiasm and confidence are accumulating based not only on the encouraging results of current clinical trials but also largely on promising preclinical findings. In this article, we summarize causes of glioblastoma-mediated immune suppression, review the current and potential approaches against several key immunosuppressive regulators, and discuss the challenges and future of immunotherapy in glioblastoma treatment.
copyright © 2003–2020 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum